SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (1648)1/9/2006 1:27:57 PM
From: tuck  Read Replies (1) of 1826
 
Here's a threat to Aloxi I was unaware off, and it's perhaps not that far off:

>>SOUTH SAN FRANCISCO, Calif. (AP) -- Hana Biosciences Inc. said Monday that its oral spray for chemotherapy-induced nausea and vomiting proved equivalent to an existing product in a clinical trial.
The study included 32 patients who received either Hana's Zensana drug or GlaxosmithKline's Zofran.

Hana said it is completing additional trials needed for approval of the therapy before applying to the Food and Drug Administration in the second quarter of 2006. Hana expects to launch Zensana in 2007.

The company's shares rose 15 cents, or 2.5 percent, to $6.10 in midday trading on the American Stock Exchange.

Nausea is a common side effect of the chemotherapy drugs taken by most cancer patients.<<

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News